Brain Tumors

UCSF Protocol No. ClinicalTrials.gov Protocol No. PI Name Title
 Pediatric Cancers > Brain Tumors
14083 NCT02124772 Mueller, Sabine An Open-Label, Dose-Escalation, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the MEK Inhibitor Trametinib in Children and Adolescents Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Children and Adolescents With Cancers Harboring V600 Mutations
18083 NCT03749187 Mueller, Sabine A Target Validation/Phase1 Study of BGB-290 in Combination with Temozolomide in Adolescent and Young Adult IDH1/2 Newly Diagnosed and Recurrent Mutant Gliomas 
18086 NCT03893487 Mueller, Sabine A Target Validation Study of Fimepinostat in Children and Young Adults with Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG), Recurrent Medulloblastoma, or Recurrent High-Grade Glioma (HGG) 
150812 NCT02962167 Mueller, Sabine PNOC 005: A Phase 1 Study of Modified Measles Virus (MV-NIS) for the Treatment of Children and Young Adults with Recurrent Medulloblastoma or Recurrent Atypical Teratoid Rhabdoid Tumors (ATRT) 
150814 NCT02520713 Sabnis, Amit Multicenter Cohort Study To Evaluate Outcomes after Receipt of Targeted Therapy Matched to an Individualized Cancer Therapy (iCat) Recommendations in Children and Young Adults with Solid Tumors: The iCat2, GAIN Consortium Study
160825 NCT03690869 Mueller, Sabine A Safety and Pharmacokinetic Study of Single Agent REGN2810 in Pediatric Patients With Relapsed or Refractory Solid or Central Nervous System (CNS) Tumors and a Safety and Efficacy Trial of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma, Newly Diagnosed High-Grade Glioma, or Recurrent High-Grade Glioma
160829 NCT02909777 Vo, Kieuhoa Phase 1 Trial of CUDC-907 in Children and Young Adults with Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma
170819 NCT03330197 Mueller, Sabine A Phase I/II Study of Ad-RTS-hIL-12, an Inducible Adenoviral Vector Engineered to Express hIL-12 in the Presence of the Activator Ligand Veledimex in Pediatric Brain Tumor Subjects
180812   Reddy, Alyssa Telemedicine in Pediatric Neuro-Oncology Patients: A Feasibility and Pilot Randomized Control Trial
180823 NCT03579602 Mueller, Sabine A randomized, blinded study of fluorescence detection of pediatric primary central nervous system tumors in subjects receiving tozuleristide and imaged with the Canvas System
ADVL1823 NCT03834961 Vo, Kieuhoa Larotrectinib (LOXO-101, NSC# 788607) for Previously Untreated TRK Fusion Pediatric Solid Tumors and TRK Fusion Relapsed Pediatric Acute Leukemias
 Pediatric Cancers > Brain Tumors > Glioma
160831 NCT03429803 Mueller, Sabine A Phase I Study of TAK- 580 (MLN2480) for Children with Low-Grade Gliomas and Other RAS/RAF/MEK/ERK/ Pathway Activated Tumors 
190815 NCT04323046 Mueller, Sabine A Randomized, Double- Blinded, Pilot, Trail of Neoadjuvant Checkpoint Inhibition Followed by Combination Adjuvant Checkpoint Inhibition in Children and Young Adults with Reccurrent or Progressive High Grade Glioma (HGG)
190819 NCT04485559 Mueller, Sabine A Phase I Trial Evaluating the Combination of Trametinib and Everolimus in Pediatric and Young Adult Patients with Recurrent Low-Grade Gliomas
150819 NCT02960230 Mueller, Sabine H3.3K27M Specific Peptide Vaccine Combined with poly-ICLC with and without PD-1 inhibition using Nivolumab for the Treatment of newly diagnosed HLA-A2 (02:01)+ H3.3K27M Positive Diffuse Intrinsic Pontine Glioma (DIPG) and newly diagnosed HLA-A2 (02:01)+ H3.3K27M Positive Gliomas
160816 NCT03086616 Mueller, Sabine PNOC009: A Phase I and Early Efficacy Study of Convection Enhanced Delivery of Irinotecan Liposome Injection Using Real Time Imaging with Gadolinium in Children with Diffuse Intrinsic Pontine Glioma 
170817 NCT03566199 Mueller, Sabine An Open Label Single Arm Phase I/II Study of MTX110 Delivered by Convection-Enhanced Delivery (CED) in Patients with Diffuse Intrinsic Pontine Glioma (DIPG) Previously Treated with External Beam Radiation Therapy
170827 NCT03739372 Mueller, Sabine A Pilot Trial Testing the Clinical Benefit of Using Molecular Profiling to Determine an Individualized Treatment Plan in Children and Young Adults with High Grade Glioma (Excluding Diffuse Intrinsic Pontine Glioma)
180820 NCT03416530 Kline, Cassie ONC201 in Newly Diagnosed Diffuse Intrinsic Pontine Glioma and Recurrent/Refractory Pediatric H3 K27M Gliomas
ACNS1723 NCT03919071 Reddy, Alyssa

A Phase 2 Study of Dabrafenib (NSC# 763760) with Trametinib (NSC# 763093) after Local Irradiation in Newly-Diagnosed BRAF V600-Mutant High-Grade Glioma (HGG) 

ACNS1833 NCT04166409 Reddy, Alyssa

A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine Versus Selumetinib (NSC# 748727) in Newly Diagnosed or Previously Untreated Low- Grade Glioma (LGG) Not Associated With BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)

 Pediatric Cancers > Brain Tumors > Medulloblastoma > Newly Diagnosed
ACNS1422 NCT02724579 Reddy, Alyssa A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
 Pediatric Cancers > Phase 1 Clinical Trials
16081 NCT02650401 Sabnis, Amit A Phase 1/2, Open- Label, Dose- Escalation and Expansion Study of Entrectinib (RXDX-101) in Pediatrics with Locally Advanced or Metastatic Solid or Primary CNS Tumors and/or Who have No Satisfactory Treamtent Options
19082 NCT03654716 Vo, Kieuhoa Phase 1 Study of the Dual MDM2/MDMX Inhibitor ALRN-6924 in Pediatric Cancer
 Pediatric Cancers > Rare Tumors
ADVL1622 NCT02867592 Vo, Kieuhoa Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults with Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors
 Pediatric Cancers > Relapsed/Refractory Pediatric Tumors 
150816 NCT02601937 Vo, Kieuhoa A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma
160825 NCT03690869 Mueller, Sabine A Safety and Pharmacokinetic Study of Single Agent REGN2810 in Pediatric Patients With Relapsed or Refractory Solid or Central Nervous System (CNS) Tumors and a Safety and Efficacy Trial of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma, Newly Diagnosed High-Grade Glioma, or Recurrent High-Grade Glioma
160831 NCT03429803 Mueller, Sabine A Phase I Study of TAK- 580 (MLN2480) for Children with Low-Grade Gliomas and Other RAS/RAF/MEK/ERK/ Pathway Activated Tumors 
ADVL1414 NCT02323880 Vo, Kieuhoa A Phase 1 Study of Selinexor (KPT-330), a Selective XPO1 Inhibitor, in Recurrent and Refractory Pediatric Solid Tumors, including CNS Tumors
ADVL1514 NCT02975882 Vo, Kieuhoa A Phase 1 Study of ABI-009 (nab-Rapamycin) in Pediatric Patients with Recurrent or Refractory Solid Tumors, Including CNS Tumors as a Single Agent and in Combination with Temozolomide and Irinotecan
ADVL1615 NCT03323034 Vo, Kieuhoa A Phase 1 Study of Pevonedistat (MLN4924), a NEDD8 Activating Enzyme (NAE) Inhibitor, in Combination with Temozolomide and Irinotecan in Pediatric Patients with Recurrent or Refractory Solid Tumors
ADVL1711 NCT03245151 Vo, Kieuhoa A Phase 1/2 Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors
ADVL1921 NCT03709680 Vo, Kieuhoa PHASE 1 STUDY TO EVALUATE THE SAFETY AND PHARMACOKINETICS OF PALBOCICLIB (IBRANCE®) IN COMBINATION WITH IRINOTECAN AND TEMOZOLOMIDE IN PEDIATRIC PATIENTS WITH RECURRENT OR REFRACTORY SOLID TUMORS
APEC1621A NCT03213704 Rangaswami, Arun NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-101 (Larotrectinib) in Patients with Tumors Harboring Actionable NTRK Fusions
APEC1621B NCT03210714 Rangaswami, Arun NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of JNJ-42756493  (Erdafitinib) in Patients with Tumors Harboring FGFR1/2/3/4 Alterations
APEC1621C NCT03213665 Rangaswami, Arun NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Tazemetostat in Patients with Tumors Harboring Alterations in EZH2 or Members of the SWI/SNF Complex
APEC1621D NCT03213678 Rangaswami, Arun NCI-COG Pediatric MATCH (Molecular Analysis For Therapy Choice)- Phase 2 Subprotocol of Ly3023414 in Patients with Solid Tumors
APEC1621E    NCT03213691 Rangaswami, Arun NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Selumetinib (AZD6244 Hydrogen Sulfate) in Patients With Tumors Harboring Activating MAPK Pathway Mutations
APEC1621F NCT03213652 Rangaswami, Arun NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Ensartinib in Patients with Tumors Harboring ALK or ROS1 Genomic Alterations
APEC1621G NCT03220035 Rangaswami, Arun NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Vemurafenib in Patients with Tumors Harboring Braf V600 Mutations
APEC1621H NCT03233204 Rangaswami, Arun NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Olaparib in Patients with Tumors Harboring Defects in DNA Damage Repair Genes
APEC1621I NCT03526250 Rangaswami, Arun NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Palbociclib in Patients With Tumors Harboring Activating Alterations in Cell Cycle Genes
APEC1621J NCT03698994 Rangaswami, Arun NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of BVD-523FB (Ulixertinib) in Patients With Tumors Harboring Activating MAPK Pathway Mutations
APEC1621SC NCT03155620 Rangaswami, Arun NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol